Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
09/21/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective September 20, 2018, the compensation committee of the company’s board of directors granted 6 new employees and a Vice President, Corporate Communications and Public Affairs, options to purchase an aggregate of 128,000 and 45,000 shares of the company’s common stock, respectively, with a per share exercise price of $16.35, the closing trading price on the grant date.... 
09/17/18Coherus BioSciences Management to Present at the 2018 Cantor Global Healthcare Conference in October
REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, October 2, 2018 at 8:00 am ET. The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com. About Coherus BioSciences, Inc. Coherus is a leading biosimilar company that... 
08/20/18Coherus BioSciences Management to Participate in Two Investor Healthcare Conferences in September 
REDWOOD CITY, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will participate in two upcoming investor healthcare conferences in September. Management participation in a fireside chat is scheduled at Baird’s 2018 Global Healthcare Conference on Wednesday, September 5th at 10:50 a.m. ET taking place in New York, NY. Management participation in a fireside chat is scheduled at the 13th Annual Wells Fargo Securit... 
08/17/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 14, 2018, the company’s board of directors granted 3 new employees options to purchase an aggregate of 35,500 shares of the company’s common stock with a per share exercise price of $19.40, the closing trading price on the grant date. The company also announced that the company’s board of directors granted one new employee and a Vice President, Drug Safety and... 
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$16.10
Change (%) Stock is Up 0.15 (0.94%)
Volume543,199
Data as of 09/24/18 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet